Das et al., 2011 - Google Patents
Preparation of patient doses of 177Lu-DOTA-TATE using indigenously produced 177Lu: the Indian experienceDas et al., 2011
View HTML- Document ID
- 9453873624378911881
- Author
- Das T
- Chakraborty S
- Kallur K
- Venkatesh M
- Banerjee S
- Publication year
- Publication venue
- Cancer Biotherapy and Radiopharmaceuticals
External Links
Snippet
Purpose: 177Lu (T 1/2= 6.73 days, E β (max)= 0.497 MeV, E γ= 113 KeV [6.4%] and 208 KeV [11%])-labeled DOTA-TATE, a somatostatin analog, is presently being considered a promising agent for the treatment of patients suffering from inoperable neuroendocrine …
- 238000002360 preparation method 0 title abstract description 46
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/001—Recovery of specific isotopes from irradiated targets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | First-in-human PET/CT imaging of metastatic neuroendocrine neoplasms with cyclotron-produced 44Sc-DOTATOC: a proof-of-concept study | |
| Huclier-Markai et al. | Promising scandium radionuclides for nuclear medicine: a review on the production and chemistry up to in vivo proofs of concept | |
| Chakravarty et al. | Availability of yttrium-90 from strontium-90: a nuclear medicine perspective | |
| Kumar | The current status of the production and supply of gallium-68 | |
| Grubmueller et al. | 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: first in-human studies | |
| Riondato et al. | Oldie but goodie: Is technetium-99m still a treasure trove of innovation for medicine? A patents analysis (2000–2022) | |
| Baggish et al. | Radiopharmaceutical agents for myocardial perfusion imaging | |
| Liu et al. | 68Ga/177Lu-labeled DOTA-TATE shows similar imaging and biodistribution in neuroendocrine tumor model | |
| Raffel et al. | First-in-human studies of [18F] fluorohydroxyphenethylguanidines: positron emission tomography radiotracers for quantifying regional cardiac sympathetic nerve density | |
| Liang et al. | First human use of a radiopharmaceutical prepared by continuous-flow microfluidic radiofluorination: proof of concept with the tau imaging agent [18F] T807 | |
| Gutfilen et al. | Radiopharmaceuticals in nuclear medicine: recent developments for SPECT and PET studies | |
| Minutoli et al. | Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature | |
| Mastren et al. | Cyclotron production of high–specific activity 55Co and in vivo evaluation of the stability of 55Co metal-chelate-peptide complexes | |
| Chakravarty et al. | Long-term evaluation of ‘BARC 68Ge/68Ga generator’based on the nanoceria-polyacrylonitrile composite sorbent | |
| Abou et al. | Radiopharmaceutical quality control considerations for accelerator-produced actinium therapies | |
| Das et al. | Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP | |
| Shukla et al. | Development of 68Ga DOTA-CRH for PET/CT imaging of ACTH-dependent Cushing's disease: initial study | |
| Chakraborty et al. | The practicality of nanoceria-PAN-based 68Ge/68Ga generator toward preparation of 68Ga-labeled cyclic RGD dimer as a potential PET radiotracer for tumor imaging | |
| Zaid et al. | Mathematical modeling of in vivo alpha particle generators and chelator stability | |
| Alavi et al. | 177Lu/153Sm-Ethylenediamine tetramethylene phosphonic acid cocktail: A novel palliative treatment for patients with bone metastases | |
| Das et al. | Preparation of patient doses of 177Lu-DOTA-TATE using indigenously produced 177Lu: the Indian experience | |
| Lee et al. | Spatial resolution and image qualities of Zr-89 on Siemens Biograph TruePoint PET/CT | |
| Mittal et al. | Synthesis and biological evaluation of 90Y-labeled porphyrin-DOTA conjugate: a potential molecule for targeted tumor therapy | |
| Kovan et al. | An analysis for therapeutic doses of patients with neuroendocrine tumor treated with lutetium 177 (177Lu)-DOTATATE | |
| De Decker et al. | Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131 |